Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific filings document the company’s public reporting for its common stock and Nasdaq-listed warrants, including CORZZ tranche 2 warrants exercisable for common stock at a $0.01 exercise price. The records identify Core Scientific as a digital infrastructure business with bitcoin self-mining, digital asset hosting and high-density colocation operations.
Recent 8-K filings cover operating and financial results, Regulation FD materials, material definitive agreements, securities registered under Section 12(b), senior secured notes due 2031, capital-structure disclosures, subsidiary financing arrangements and governance matters such as officer appointments and compensation arrangements.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of $17 that expire on February 20, 2026. The position is held through various funds and accounts that have delegated sole voting and investment power to Two Seas Capital.
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.
Situational Awareness entities and two individuals filed a Schedule 13D reporting shared beneficial ownership of 17,682,918 shares of Core Scientific, Inc. common stock, representing 5.8% of the class based on 305,408,442 shares outstanding as of August 5, 2025. The filing states the Fund used $213,190,431.12 of working capital to acquire the shares, largely through a series of open-market purchases in July and August 2025 at prices reported between $13.189 and $14.9047 per share. The reporting persons say the stock was acquired for investment because they considered it undervalued and they reserve the right to buy, sell, hedge, or communicate with other stakeholders, but currently have no present plan to effect specific corporate changes.
Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc. (CORZ), reported a Form 4 disclosing a transaction dated 08/15/2025. The filing shows 11,805 shares of Common Stock were disposed under transaction code F(1) at a price of $14.13 per share; the filing explains these shares were withheld to satisfy tax withholding upon vesting of restricted stock units. Following the withholding, Mr. DuChene beneficially owns 2,029,656 shares, held directly. The Form 4 is signed and dated 08/19/2025 by the reporting person.
Reporting persons G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC disclose an aggregate beneficial ownership of 18,336,176 shares of Core Scientific, Inc. common stock, representing 6.2% of the class based on the company’s reported 297,821,835 shares outstanding. The reported position includes direct holdings and securities exercisable or convertible into shares, including options and warrants.
The filing states these affiliated broker-dealers may be deemed a group and reports both sole and shared voting and dispositive power across the reporting persons. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing control. Investors should note that part of the position derives from options, warrants or convertible instruments and therefore may reflect potential dilution rather than current free-floating shares.
Core Scientific reported a large headline net loss driven primarily by non-cash changes in derivative valuations, while its operating business shows mixed trends. Cash and cash equivalents declined to $581.3 million from $836.2 million, but the company materially increased its bitcoin holdings to 1,612 BTC with a fair value of $172.8 million. Total assets rose to $1.978 billion and property, plant and equipment, net increased to $828.6 million, reflecting ongoing capital investment.
Revenue fell versus prior year to $78.6 million for the quarter, producing a small gross profit but operating losses as selling, general and administrative costs rose. Large non-operating items included a $923.5 million increase in the fair value of Tranche 2 warrants recorded as expense, producing a three-month net loss of $936.8 million. Warrant liabilities total $1.3167 billion, convertible debt remains significant, and contractual capital commitments total approximately $1.71 billion. The company disclosed the proposed acquisition by CoreWeave and detailed related transaction risks.
Core Scientific, Inc. furnished a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Items 2.02 and 7.01 of the filing. The company states that the information in Items 2.02 and 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference in Securities Act filings.
The 8-K itself does not include the underlying financial metrics or operational detail; readers must review Exhibit 99.1 for the actual results. The filing also lists the registrant's exchange-listed securities: common stock CORZ and warrants CORZW and CORZZ.
Two Seas Capital LP, together with its general partner and CIO Sina Toussi, filed a Schedule 13D disclosing beneficial ownership of 19,122,842 Core Scientific (CORZZ) shares, or 6.3 % of the outstanding common stock. The position is held across the firm’s Strategic Fund, Global Fund and two managed accounts and includes 5.72 m options and 313.6 k warrants. Aggregate consideration for the shares, options and warrants totals roughly $133.9 million, funded with the working capital of the funds/accounts.
The filing signals an activist stance: on 7 Aug 2025 Two Seas issued an open letter stating it will vote against the proposed merger between Core Scientific and CoreWeave and intends to solicit proxies opposing the deal at the forthcoming special meeting. The filer may engage management and other shareholders, and could adjust its exposure through additional purchases, sales or hedging transactions—including swaps that reference a notional 500 k shares—depending on market conditions and strategic considerations.